Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis

Antifibrotic therapies reduce mortality and hospitalization among Medicare beneficiaries with idiopathic pulmonary fibrosis

BACKGROUND: Additional real-world studies are needed to more fully elucidate the effectiveness of antifibrotic treatment in slowing the progression of idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To compare mortality and hospitalization between Medicare beneficiaries with IPF who initiate antifib...

Full description

Bibliographic Details
Main Authors: Broder, M.S (Author), Chang, E. (Author), Corral, M. (Author), Gokhale, S. (Author), Mooney, J. (Author), Reddy, S.R (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
aged
Aged
Aged, 80 and over
ambulatory care
antifibrotic agent
Antifibrotic Agents
antifibrotic therapy
Article
atrial fibrillation
congestive heart failure
controlled study
corticosteroid
corticosteroid therapy
economics
female
Female
fibrosing alveolitis
follow up
gastroesophageal reflux
hospitalization
Hospitalization
human
Humans
Idiopathic Pulmonary Fibrosis
income
ischemic heart disease
lung cancer
major clinical study
male
Male
medicare
Medicare
mortality
Mortality
mortality risk
nintedanib
observational study
pirfenidone
pneumonia
pneumothorax
protein kinase inhibitor
Protein Kinase Inhibitors
pulmonary rehabilitation
residential area
Retrospective Studies
retrospective study
sleep disordered breathing
smoking cessation
United States
very elderly
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items